ArticleClinical lymphoma, myeloma & leukemia2013
Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience.
Article in Clinical lymphoma, myeloma & leukemia, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic review: hepatosplenic T-cell lymphoma on biologic therapy for inflammatory bowel disease, including data from the Food and Drug Administration Adverse Event Reporting System.Alimentary pharmacology & therapeutics · 2020Pooled it
- Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial.Leukemia · 2021Trial
- Clinical heterogeneity of primary cutaneous γδ T-cell lymphoma: a 20-year single-institution experience.Blood research · 2026Article
- A Case of Hepatosplenic Gamma Delta T Cell Lymphoma With Concomitant Bone Marrow Aplasia Following Azathioprine Therapy, Treatment Course and Review of the Literature.Cancer reports (Hoboken, N.J.) · 2025Review
- Hepatosplenic T-cell lymphoma in children and adolescents.Blood advances · 2025Review
- Allo-HSCT with TBI-based preconditioning for hepatosplenic T-cell lymphoma: two case reports and systematic review of literature.Frontiers in oncology · 2024Article
- Few and far between: clinical management of rare extranodal subtypes of mature T-cell and NK-cell lymphomas.Haematologica · 2023Review
- SOHO State of the Art Updates and Next Questions | Challenging Cases in Rare T-Cell Lymphomas.Clinical lymphoma, myeloma & leukemia · 2023Review
- Retrospective analysis of diagnosis and therapeutic strategies for patients with hepatosplenic T cell lymphoma.Annals of hematology · 2023Article
- Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome.Haematologica · 2023Article
- Successful treatment of hepatosplenic T-cell lymphoma with fludarabine, high-dose cytarabine and subsequent unrelated umbilical cord blood transplantation.International journal of hematology · 2022Article
- Clinical features and treatment outcomes of 14 patients with hepatosplenic γ δ T-cell lymphoma.Journal of cancer research and clinical oncology · 2021Article
- Survival Analysis of Hepatosplenic T Cell Lymphoma: A Population-Based Study Using SEER.International journal of general medicine · 2021Article
- Review
- A case of hepatosplenic T-cell lymphoma successfully treated by HLA haploidentical stem cell transplantation.Journal of clinical and experimental hematopathology : JCEH · 2020Article
- Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders with a T- or NK-cell phenotype.Journal of clinical and experimental hematopathology : JCEH · 2019Review
- An unusual presentation of an uncommon lymphoma, hepatosplenic T-cell lymphoma.Proceedings (Baylor University. Medical Center) · 2019Article
- Article
- Use of PEG-asparaginase in a case of Hepatosplenic γδ T-cell lymphoma with long-term remission after stem cell transplantation.Ecancermedicalscience · 2018Article
- Hepatosplenic T-cell lymphoma arising in patients with immunodysregulatory disorders: a study of 7 patients who did not receive tumor necrosis factor-α inhibitor therapy and literature review.Annals of diagnostic pathology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionHepatosplenic T-cell lymphoma is a rare form of extranodal non-Hodgkin lymphoma, first recognized as a distinct entity in the Revised European-American Lymphoma classification. Typical presentation includes lymphomatous infiltration of spleen and liver, and peripheral lymphadenopathy is rarely seen. The prognosis is almost uniformly poor, and there are no prospective studies of treatment of HSTCL. PATIENTS AND
methodsFor this report, we conducted a retrospective review of all pts who underwent treatment for HSTCL at our institution. Individual chart review was performed to report clinical presentation, management, and outcome.
resultsWe identified 14 pts with HSTCL managed at our center, 7 of which remain alive with median follow-up of 65.6 months. Six of 7 received alternative induction chemotherapy regimens such as ICE (ifosfamide, carboplatin, etoposide) or IVAC (ifosfamide, etoposide, high-dose cytarabine) as opposed to CHOP and all surviving pts had proceeded to undergo either autologous or allogeneic SCT.
conclusionOur results suggest that use of non-CHOP induction regimen and early use of high dose therapy and SCT consolidation may translate to improved survival for pts with HSTCL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.